2 active not recruiting, 2 completed, 2 terminated. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Neurogene Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome NGN-401 - Rett Syndrome | Phase 3 | Active not recruiting | Neurogene Inc. | 33 | 2023-06-13 | 2026-06-10 |
| Gene Therapy Study for Children With CLN5 Batten Disease NGN-101 - Neuronal Ceroid Lipofuscinosis CLN5 | Phase 1 / Phase 2 | Active not recruiting | Neurogene Inc. | 6 | 2022-01-31 | 2024-08-12 |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer NL-201, Pembrolizumab Injection [Keytruda] - Solid Tumor, Advanced Solid Tumor | Phase 1 | Completed | Neurogene Inc. | 59 | 2021-04-26 | 2024-10-01 |
| A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) Charcot-Marie-Tooth Disease, Hereditary Motor and Sensory Neuropathy IV | Terminated | Neurogene Inc. | 21 | 2019-07-18 | 2022-03-31 | |
| A Natural History Study of Aspartylglucosaminuria Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency | Terminated | Neurogene Inc. | 8 | 2019-04-18 | 2022-04-12 | |
| A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5) Ceroid Lipofuscinosis, Neuronal 5 | Completed | Neurogene Inc. | 37 | 2019-03-13 | 2024-06-27 |
Aspartylglucosamidase (AGA) deficiency (1) · Aspartylglucosaminuria (1) · Ceroid lipofuscinosis, neuronal 5 (1) · Charcot-Marie-Tooth Disease (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Intellectual Disability (1) · Lysosomal Storage Diseases (1) · Neoplasms (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurodevelopmental Disorders (1) · Neurologic Manifestations (1) · Neuronal Ceroid-Lipofuscinoses (1) · Pathologic Processes (1)
pembrolizumab (1)
United States (6) · Australia (2) · United Kingdom (2) · Canada (1)
Elise Beausoleil (3) · Albiruni A Razak (1) · Effie Albanis, MD (1) · Julie Jordan, MD (1)